Bioconjugation

Omniose Announces Scientific Collaboration With AstraZeneca to Research Vaccines for Serious Bacterial Diseases

Retrieved on: 
Friday, January 5, 2024
Medical Supplies, Health, Infectious Diseases, Research, Science, Pharmaceutical, Biotechnology, Vaccine, CSO, Immunization, Immunity (medical), Membrane, Bioconjugation, Synthetic biology, Infection, Conjugation, AstraZeneca

Omniose, a preclinical biotechnology company, today announced an exclusive collaboration agreement with AstraZeneca to research potential vaccines for bacterial pathogens in AstraZeneca’s early Vaccines & Immune Therapies pipeline.

Key Points: 
  • Omniose, a preclinical biotechnology company, today announced an exclusive collaboration agreement with AstraZeneca to research potential vaccines for bacterial pathogens in AstraZeneca’s early Vaccines & Immune Therapies pipeline.
  • Under the terms of the agreement, AstraZeneca will have exclusive rights to Omniose’s proprietary bioconjugation platform for up to three years, which allows for the development of high-quality vaccines against a range of bacterial pathogens, including multidrug-resistant “superbugs” previously intractable by other methods.
  • Conjugate vaccines are an effective form of immunization however, their use is limited due to the complex chemical process of attaching bacterial polysaccharides to engineered carrier proteins.
  • As part of our ambition to provide long-lasting immunity to millions of people, we are excited to enter into this scientific collaboration with Omniose to explore the role of this novel bioconjugate platform in developing vaccines for bacterial pathogens.”

Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer

Retrieved on: 
Tuesday, October 17, 2023
Bioconjugation, DPS, CH, USD, CHF, CGMP, Growth, Hook effect, Spacecraft, CDMO, ADC, Fine chemical

Under the terms of the agreement, Lonza will construct a dedicated commercial-scale aseptic cGMP filling line at its Stein (CH) site.

Key Points: 
  • Under the terms of the agreement, Lonza will construct a dedicated commercial-scale aseptic cGMP filling line at its Stein (CH) site.
  • The new dedicated filling line will enable the aseptic filling of highly-potent ADCs and lyophilization under containment.
  • The additional filling capabilities further strengthen Lonza's capacity and flexibility in supporting both clinical and commercial supply of bioconjugates.
  • The additional filling line in Stein (CH) marks another milestone in the growth of Lonza’s leading Drug Product Services (DPS) offering.

Global Conjugation and Labeling Services Market to 2035: Rising Demand for Conjugated Biomolecules in the Field of Research and Development Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 12, 2023
Health, Pharmaceutical, Molecule, Bioconjugation, Therapy, Administration, Hapten, Enzyme, Polymer, Research, Antibody, Organization, Protein, Membrane, Conjugation, Bioconjugate Chemistry, Isotope, ChromeOS, Peptide, Fine chemical, Vaccine

The "Conjugation and Labeling Services Market: Focus on Protein Labeling, Peptide Labeling, Small Molecule Conjugation and Antibody Conjugation: Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Conjugation and Labeling Services Market: Focus on Protein Labeling, Peptide Labeling, Small Molecule Conjugation and Antibody Conjugation: Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.
  • This report features an extensive study of the current market landscape, market size and the likely future potential of the conjugation and labeling services market, during the forecast period.
  • Further, given the rising demand for conjugated biomolecules in the field of research and development, the conjugation and labeling services market is anticipated to witness substantial growth in the foreseen future.
  • These factors together will be responsible for market growth through increased outsourcing of protein labeling, antibody labeling and antibody conjugation services to the CROs.

Omniose Awarded $3.6 Million Grant from NIH to Develop Vaccines against Klebsiella pneumoniae

Retrieved on: 
Tuesday, October 11, 2022
Medical Supplies, Health, Infectious Diseases, Other Science, Pharmaceutical, Science, National Institute, Workplace safety in healthcare settings, Infection, IND, Pneumonia, Bloodstream infections, Vaccine, NIH, Enzyme, Lancet, Klebsiella pneumoniae, CEO, Bioconjugation, National Institute of Allergy and Infectious Diseases, Protein, Child, Death, Subclinical infection, View, Klebsiella

Klebsiella pneumoniae has developed resistance to many classes of antimicrobials and was attributed to or associated with an estimated 600,000 deaths globally in 20193.

Key Points: 
  • Klebsiella pneumoniae has developed resistance to many classes of antimicrobials and was attributed to or associated with an estimated 600,000 deaths globally in 20193.
  • Timothy Cooke, CEO, added This NIH grant funding allows Omniose to extend our on-going efforts to combat serious infections due to Klebsiella.
  • Omniose is utilizing its proprietary bioconjugation platform to develop novel polysaccharide protein conjugate vaccines targeting K. pneumoniae4.
  • K. pneumoniae produces multiple surface polysaccharides, including a capsular polysaccharide (capsule) and a lipopolysaccharide decorated with an O-antigen polysaccharide (O-antigen).

Omniose Announces Expanded Leadership Team to Develop Bioconjugate Vaccines Against Serious Bacterial Threats

Retrieved on: 
Tuesday, April 19, 2022
Biotechnology, Infectious Diseases, Other Health, Health, Pharmaceutical, Protein, CEO, Infection, MBA, United States Air Force Scientific Advisory Board, Research, Enzyme, Science, Entrepreneurship, Doctor of Philosophy, Novartis, Vaccine, Engineering, MedImmune, Policy, Bioconjugation, Industry, Tobacco Products Scientific Advisory Committee, Biotechnology industry in China, Antimicrobial resistance, Pharmaceutical industry

Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, announced today the expansion of the leadership team to include Timothy Cooke, Ph.D., MBA as Chief Executive Officer and Roman Fleck.

Key Points: 
  • Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, announced today the expansion of the leadership team to include Timothy Cooke, Ph.D., MBA as Chief Executive Officer and Roman Fleck.
  • The research team will be led by Christian Harding, Ph.D., Chief Scientific Officer and Co-Founder of Omniose.
  • Omniose combines great science with a dedicated team on a mission to protect people from serious bacterial infections, said Timothy Cooke, CEO.
  • Our approach greatly expands the universe of bacterial targets that can be addressed by bioconjugate vaccines.

Vincerx Pharma to Participate in the Jefferies Virtual Healthcare Conference

Retrieved on: 
Wednesday, May 26, 2021
Life sciences, Natural sciences, Biotechnology, Clinical medicine, Antibody-drug conjugate, Immunology, Bioconjugation, Medication

The presentation will be webcast live and archived in the Investors section of the Companys website.

Key Points: 
  • The presentation will be webcast live and archived in the Investors section of the Companys website.
  • Vincerx Pharma, Inc.(Vincerx) is a clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer.
  • Vincerx has assembled a management team of biopharmaceutical experts with extensive experience in building and operating organizations that develop and deliver innovative medicines to patients.
  • Vincerxs current pipeline is derived from an exclusive license agreement with Bayer and includes a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation platform, which includes next-generation antibody-drug conjugates and innovative small molecule drug conjugates.

NJ Bio Moves Headquarters to Princeton, New Jersey

Retrieved on: 
Tuesday, May 4, 2021
Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Natural sciences, Biochemistry, Bioconjugation, Chemical bonding, Bristol Myers Squibb, Life sciences, Biotechnology

View the full release here: https://www.businesswire.com/news/home/20210504005811/en/\nNew Headquarters for NJ Bio at 350 Carter Road, Princeton, NJ (Photo: Business Wire)\nThe 35,000-square-foot, state-of-the-art laboratory space will be located at 350 Carter Road, at a site formerly occupied by Bristol Myers Squibb .

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210504005811/en/\nNew Headquarters for NJ Bio at 350 Carter Road, Princeton, NJ (Photo: Business Wire)\nThe 35,000-square-foot, state-of-the-art laboratory space will be located at 350 Carter Road, at a site formerly occupied by Bristol Myers Squibb .
  • NJ Bio will continue to operate its facility in Bristol, PA, with plans for future growth at that site, including GMP manufacturing capabilities for small molecules as well as bioconjugation.\n\xe2\x80\x9cOn behalf of the board of directors and senior management at NJ Bio, I am excited to announce this move,\xe2\x80\x9d said Nareshkumar Jain , Ph.D., President and CEO of NJ Bio.
  • \xe2\x80\x9cOur expansion to this advanced facility demonstrates the rapid growth of NJ Bio in just over two years.
  • NJ Bio also offers expertise in flow chemistry and process development and provides innovative solutions for large-scale continuous manufacturing needs.

Vincerx Pharma to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Wednesday, February 17, 2021
Life sciences, Biotechnology, Natural sciences, Specialty drugs, Antibody-drug conjugate, Immunology, Biopharmaceutical, Bioconjugation

The presentation will be webcast live and archived for 90 days in the Investors section of the Companys website.

Key Points: 
  • The presentation will be webcast live and archived for 90 days in the Investors section of the Companys website.
  • Vincerx Pharma (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer.
  • Vincerxs executive team has assembled a management team of biopharmaceutical experts with extensive experience in building and operating organizations that develop and deliver innovative medicines to patients.
  • Vincerxs current pipeline is derived from an exclusive license agreement with Bayer and includes a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation antibody-drug conjugate platform.

Oligonucleotide ADC Design and Development - An Emerging Field Building on the Success of ADCs in Cancer, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Friday, January 29, 2021
Biotechnology, Nucleic acids, Life sciences, Natural sciences, Antibody-oligonucleotide conjugate, Biology, Bioconjugation

Antibody-oligonucleotide conjugates (AOCs) are a growing sub-class of ADCs that utilize the oligonucleotide functionality in combination with the antibody's exquisite targeting ability and improved biodistribution profile.

Key Points: 
  • Antibody-oligonucleotide conjugates (AOCs) are a growing sub-class of ADCs that utilize the oligonucleotide functionality in combination with the antibody's exquisite targeting ability and improved biodistribution profile.
  • Oligonucleotides, as drug molecules, suffer from several drawbacks such as instability, impaired pharmacokinetics (PK), poor cellular uptake and sub-optimal tissue targeting.
  • In this webinar, panelists will review oligonucleotide bioconjugates focusing upon their design, development, analysis and manufacture.
  • For more information, or to register for this event, visit Oligonucleotide ADC Design and Development An Emerging Field Building on the Success of ADCs in Cancer.

Vincera Pharma, Inc Announces Exclusive License Agreement for Oncology Portfolio Including a Clinical-stage PTEFb/CDK9 Inhibitor and a Preclinical Bioconjugation Platform

Retrieved on: 
Thursday, October 8, 2020
Branches of biology, Proteins, Biology, Natural sciences, Biochemistry, Bioconjugation, Chemical bonding, Cyclin-dependent kinase 9, P-TEFb, Antibody-drug conjugate

Under the terms of the license agreement, Vincera will in-license VIP152 (formerly BAY 1251152), a clinical-stage, highly selective, positive transcription elongation factor b (PTEFb)/cyclin-dependent kinase 9 (CDK9) inhibitor for the treatment of cancer.

Key Points: 
  • Under the terms of the license agreement, Vincera will in-license VIP152 (formerly BAY 1251152), a clinical-stage, highly selective, positive transcription elongation factor b (PTEFb)/cyclin-dependent kinase 9 (CDK9) inhibitor for the treatment of cancer.
  • Additionally, Vincera will receive assets and license technology for a preclinical bioconjugation platform to address the limitations of small-molecule and antibody-drug conjugates in oncology.
  • Dr. Hamdy continued, In addition to our planned clinical program, we intend to advance, in parallel, the development of our preclinical bioconjugation platform.
  • In exchange for this license, Vincera will pay Bayer an upfront license fee and development and commercial sales milestone payments.